Skip to content

Study · Non-randomized trial · 1999

10 results

Effects of growth hormone-releasing peptide-6 on the nocturnal secretion of GH, ACTH and cortisol and on the sleep EEG in man: role of routes of administration.

Frieboes RM, Murck H, Antonijevic IA, Steiger A

Journal of neuroendocrinology1 Jun 1999Cited by 15 (Europe PMC)

PMID10336729 (opens in a new tab)DOI10.1046/j.1365-2826.1999.00364.x (opens in a new tab)PepBankPUB-10336729
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In healthy young men, oral GHRP‑6 did not change nocturnal GH secretion versus placebo.

    In plain wordsIn healthy young men, GHRP‑6 taken by mouth did not change night-time growth hormone compared with placebo.

    Peptide
    GHRP-6
    Outcome
    No significant changeNocturnal GH secretion after oral GHRP-6
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    300 microg/kg body weight · oralAs given in this study (human).

    Source sentences

    Summary
    After GHRP-6 p.o. secretion of GH, ACTH and cortisol remained unchanged.
    1 context sentence
    Summary · context
    We compared the sleep-endocrine effects of 300 microg/kg of body weight (b.w.) GHRP-6 in enteric-coated capsules given p.o. at 21.00 h and of 30 microg/kg GHRP-6 i.n. or 30 microg/kg GHRP-6 sl. given at 22.45 h in normal young male controls with placebo conditions.
  2. 02HumanNon-randomized trialEfficacy outcome

    In healthy young men, oral GHRP‑6 did not change nocturnal ACTH secretion versus placebo.

    In plain wordsIn healthy young men, GHRP‑6 taken by mouth did not change night-time ACTH compared with placebo.

    Peptide
    GHRP-6
    Outcome
    No significant changeNocturnal ACTH secretion after oral GHRP-6
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Stress hormones · Endocrine and hormones
    Studied dose
    300 microg/kg body weight · oralAs given in this study (human).

    Source sentences

    Summary
    After GHRP-6 p.o. secretion of GH, ACTH and cortisol remained unchanged.
    1 context sentence
    Summary · context
    We compared the sleep-endocrine effects of 300 microg/kg of body weight (b.w.) GHRP-6 in enteric-coated capsules given p.o. at 21.00 h and of 30 microg/kg GHRP-6 i.n. or 30 microg/kg GHRP-6 sl. given at 22.45 h in normal young male controls with placebo conditions.
  3. 03HumanNon-randomized trialEfficacy outcome

    In healthy young men, oral GHRP‑6 did not change nocturnal cortisol secretion versus placebo.

    In plain wordsIn healthy young men, GHRP‑6 taken by mouth did not change night-time cortisol compared with placebo.

    Peptide
    GHRP-6
    Outcome
    No significant changeNocturnal cortisol secretion after oral GHRP-6
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Stress hormones · Endocrine and hormones
    Studied dose
    300 microg/kg body weight · oralAs given in this study (human).

    Source sentences

    Summary
    After GHRP-6 p.o. secretion of GH, ACTH and cortisol remained unchanged.
    1 context sentence
    Summary · context
    We compared the sleep-endocrine effects of 300 microg/kg of body weight (b.w.) GHRP-6 in enteric-coated capsules given p.o. at 21.00 h and of 30 microg/kg GHRP-6 i.n. or 30 microg/kg GHRP-6 sl. given at 22.45 h in normal young male controls with placebo conditions.
  4. 04HumanNon-randomized trialEfficacy outcome

    In healthy young men, sublingual GHRP‑6 produced only a trend toward higher GH in the first half of the night versus placebo.

    In plain wordsIn healthy young men, GHRP‑6 under the tongue showed only a trend toward more growth hormone early in the night, compared with placebo.

    Peptide
    GHRP-6
    Outcome
    No significant changeGH in first half of the night after sublingual GHRP-6
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    30 microg/kg body weight · sublingualAs given in this study (human).

    Source sentences

    Summary
    The only effect of GHRP-6 s.l. was a trend toward an increase in GH in the first half of the night.
    1 context sentence
    Summary · context
    We compared the sleep-endocrine effects of 300 microg/kg of body weight (b.w.) GHRP-6 in enteric-coated capsules given p.o. at 21.00 h and of 30 microg/kg GHRP-6 i.n. or 30 microg/kg GHRP-6 sl. given at 22.45 h in normal young male controls with placebo conditions.
  5. 05HumanNon-randomized trialEfficacy outcome

    In healthy young men, intranasal GHRP‑6 significantly increased GH concentration over the total night versus placebo.

    In plain wordsIn healthy young men, GHRP‑6 given in the nose raised growth hormone during the night compared with placebo.

    Peptide
    GHRP-6
    Outcome
    IncreaseTotal-night GH after intranasal GHRP-6
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    30 microg/kg body weight · intranasalAs given in this study (human).

    Source sentences

    Summary
    GHRP-6 i.n. prompted a significant increase in GH concentration during the total night and a trend toward an increase in ACTH secretion during the first half of the night, whereas cortisol secretion remained unchanged.
    1 context sentence
    Summary · context
    We compared the sleep-endocrine effects of 300 microg/kg of body weight (b.w.) GHRP-6 in enteric-coated capsules given p.o. at 21.00 h and of 30 microg/kg GHRP-6 i.n. or 30 microg/kg GHRP-6 sl. given at 22.45 h in normal young male controls with placebo conditions.
  6. 06HumanNon-randomized trialEfficacy outcome

    In healthy young men, intranasal GHRP‑6 produced only a trend toward higher ACTH in the first half of the night versus placebo.

    In plain wordsIn healthy young men, GHRP‑6 in the nose showed only a trend toward more ACTH early in the night, compared with placebo.

    Peptide
    GHRP-6
    Outcome
    No significant changeACTH in first half of the night after intranasal GHRP-6
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Stress hormones · Endocrine and hormones
    Studied dose
    30 microg/kg body weight · intranasalAs given in this study (human).

    Source sentences

    Summary
    a trend toward an increase in ACTH secretion during the first half of the night, whereas cortisol secretion remained unchanged.
    1 context sentence
    Summary · context
    We compared the sleep-endocrine effects of 300 microg/kg of body weight (b.w.) GHRP-6 in enteric-coated capsules given p.o. at 21.00 h and of 30 microg/kg GHRP-6 i.n. or 30 microg/kg GHRP-6 sl. given at 22.45 h in normal young male controls with placebo conditions.
  7. 07HumanNon-randomized trialEfficacy outcome

    In healthy young men, intranasal GHRP‑6 did not change cortisol secretion versus placebo.

    In plain wordsIn healthy young men, GHRP‑6 in the nose did not change cortisol compared with placebo.

    Peptide
    GHRP-6
    Outcome
    No significant changeCortisol after intranasal GHRP-6
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Stress hormones · Endocrine and hormones
    Studied dose
    30 microg/kg body weight · intranasalAs given in this study (human).

    Source sentences

    Summary
    whereas cortisol secretion remained unchanged.
    1 context sentence
    Summary · context
    We compared the sleep-endocrine effects of 300 microg/kg of body weight (b.w.) GHRP-6 in enteric-coated capsules given p.o. at 21.00 h and of 30 microg/kg GHRP-6 i.n. or 30 microg/kg GHRP-6 sl. given at 22.45 h in normal young male controls with placebo conditions.
  8. 08HumanNon-randomized trialEfficacy outcome

    In healthy young men, intranasal GHRP‑6 produced only a trend toward more sleep stage 2 in the second half of the night versus placebo.

    In plain wordsIn healthy young men, GHRP‑6 in the nose showed only a trend toward more light sleep late in the night, compared with placebo.

    Peptide
    GHRP-6
    Outcome
    No significant changeSleep stage 2 in second half of the night after intranasal GHRP-6
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Sleep · Sleep
    Studied dose
    30 microg/kg body weight · intranasalAs given in this study (human).

    Source sentences

    Summary
    after GHRP-6 i.n., sleep stage 2 increased in the second half of the night by trend
    1 context sentence
    Summary · context
    We compared the sleep-endocrine effects of 300 microg/kg of body weight (b.w.) GHRP-6 in enteric-coated capsules given p.o. at 21.00 h and of 30 microg/kg GHRP-6 i.n. or 30 microg/kg GHRP-6 sl. given at 22.45 h in normal young male controls with placebo conditions.
  9. 09HumanNon-randomized trialEfficacy outcome

    In healthy young men, intranasal GHRP‑6 produced only a trend toward lower delta power in non-REM sleep versus placebo.

    In plain wordsIn healthy young men, GHRP‑6 in the nose showed only a trend toward less deep-sleep brain activity, compared with placebo.

    Peptide
    GHRP-6
    Outcome
    No significant changeDelta power of non-REM sleep after intranasal GHRP-6
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Sleep · Sleep
    Studied dose
    30 microg/kg body weight · intranasalAs given in this study (human).

    Source sentences

    Summary
    spectral analysis of total night non-rapid eye movement (REM) sleep revealed a decrease of delta power by trend.
    1 context sentence
    Summary · context
    We compared the sleep-endocrine effects of 300 microg/kg of body weight (b.w.) GHRP-6 in enteric-coated capsules given p.o. at 21.00 h and of 30 microg/kg GHRP-6 i.n. or 30 microg/kg GHRP-6 sl. given at 22.45 h in normal young male controls with placebo conditions.
  10. 10HumanNon-randomized trialEfficacy outcome

    In healthy young men, oral GHRP‑6 decreased sleep stage 2 in the second half of the night versus placebo.

    In plain wordsIn healthy young men, GHRP‑6 taken by mouth reduced light sleep late in the night compared with placebo.

    Peptide
    GHRP-6
    Outcome
    DecreaseSleep stage 2 in second half of the night after oral GHRP-6
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Sleep · Sleep
    Studied dose
    300 microg/kg body weight · oralAs given in this study (human).

    Source sentences

    Summary
    In contrast sleep stage 2 decreased during the second half of the night after GHRP-6 p.o.
    1 context sentence
    Summary · context
    We compared the sleep-endocrine effects of 300 microg/kg of body weight (b.w.) GHRP-6 in enteric-coated capsules given p.o. at 21.00 h and of 30 microg/kg GHRP-6 i.n. or 30 microg/kg GHRP-6 sl. given at 22.45 h in normal young male controls with placebo conditions.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.